• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Alternative treatment for acute promyelocytic leukemia promising

bys25qthea
July 11, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Patients with newly-diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) plus arsenic trioxide experienced similar outcomes to patients treated with conventional ATRA plus anthracycline-based chemotherapy. 

2. Patients with APL treated with ATRA plus arsenic trioxide experienced significantly lower rates of hematologic side effects (neutropenia, thrombocytopenia, fever of unknown origin, infectious episodes) but significantly higher rates of hepatic toxic effects and prolongation of the QTc interval. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: This randomized control study showed that in newly diagnosed patients with low-to-intermediate risk APL, combination induction and consolidation therapy with ATRA and arsenic trioxide was non-inferior to the current standard-of-care treatment with ATRA-anthracycline chemotherapy. Benefits of combination therapy with arsenic trioxide were measured in terms of event-free survival at 2 years after diagnosis and appear to derive from reduced incidence of severe cytopenias, mucositis, and infections, which were more commonly associated with chemotherapy.  However, these benefits were counterbalanced by a significantly increased rate of toxic hepatic effects and prolonged QTc intervals in patients treated with ATRA-arsenic trioxide, warranting close monitoring of serum electrolytes, liver transaminases, and cardiac arrhythmias. The median follow-up period of 34.4 months suggests that future studies, potentially with larger treatment groups, will be required to investigate the longer term usage of this drug combination.

Click to read the study, published today in NEJM

Relevant Reading: Management of acute promyelocytic leukemia

RELATED REPORTS

Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer

Plant-based diets may be associated with lower risk of aggressive prostate cancer

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

In-Depth [randomized control trial]: This study compared the efficacy and adverse effect profiles of ATRA-arsenic trioxide versus standard-of-care ATRA-chemotherapy for the treatment of newly diagnosed APL classified as low-to-intermediate risk (WBC count at diagnosis ≤ 10×109 per liter).  162 patients were randomized into either treatment arm from multiple centers across three countries.

The primary end point was event-free survival at 2 years after diagnosis, with treatment failure defined as lack of complete hematologic or molecular remission after induction therapy or three consolidation courses respectively, molecular relapse, hematologic collapse, or death. The median follow-up period was 34.4 months.

97% of patients in the ATRA-arsenic trioxide group were alive and event-free at 2 years as compared with 86% in the ATRA-chemotherapy group (95% CI 2 to 22 percentage points, P<0.001 for noninferiority and P=0.02 for superiority).  Severe neutropenia and severe thrombocytopenia lasting more than 15 days were significantly more frequent in the ATRA-chemotherapy group than the ATRA-arsenic trioxide group. There were 59 episodes of fever of unknown origin and infections in the ATRA-chemotherapy group versus 26 episodes in the ATRA-chemotherapy group (P<0.001). However, 63% of patients in the ATRA-arsenic trioxide group versus 6% in the ATRA-chemotherapy group experienced severe hepatic toxicity (P<0.001).

By Matthew Growdon and Mitalee Patil

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

 

Tags: acute promyelocytic leukemiacancerhealthleukemia
Previous Post

Pneumococcal vaccine associated with a decrease in pneumonia hospitalizations

Next Post

The PIVOT trial: Radical prostatectomy versus observation [Classics Series]

RelatedReports

Fatty liver disease may independently predict high-risk coronary disease
Chronic Disease

Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer

February 1, 2023
Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
No benefit of erlotinib in combined hepatocellular carcinoma treatment
Oncology

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

January 11, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Next Post

The PIVOT trial: Radical prostatectomy versus observation [Classics Series]

Gestational weight loss may improve outcomes for obese women

African Americans, obese overrepresented in young heart failure cases

Everolimus only protects against early cardiac allograft vasculopathy

Antibiotic implants reduce surgical site infections

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options